The analyst expects a strong move up in HIMS stock due to an upcoming FDA ruling likely approving popular peptides and imposing strict market standards, which benefits HIMS.
FDA likely to approve popular peptides and impose strict standards, benefiting HIMS; peptides market not yet priced into HIMS shares.
The FDA is scheduled to meet on the 23-24th of July to rule on peptides The consensus is that a number of popular peptides will be approved Their popularity has been explosive, the FDA will likely recommend that the market for peptides should meet strict standards and be controlled…instead of rogue peptides from the black market One company benefits from this ruling: $HIMS And right now the peptides total addressable market has not been built into its share price. A strong move is expected.
| Horizon | Raw move | vs SPY |
|---|---|---|
| 1 day | +3.8% | +3.1% |
| 1 week | +14.6% | +13.3% |
| 1 month | -25.1% | -23.6% |
| 3 months | — | — |
| 6 months | — | — |